Mineralys Therapeutics, Inc. MLYS Public offering and shelf offering costs included in accounts payable and accrued liabilities

Public offering and shelf offering costs included in accounts payable and accrued liabilities at other companies

CeriBell, Inc.CBLL

$0—

FCR

FutureCrest AcquisitionFCRS

$75K—

KBO

Karbon Capital PartnersKBON

$75.37K—

SBX

SBXESBXE

$85K—

SCP

Social Commerce Partners CorporationSCPQ

$108.5K—

SVC

Stellar V Capital Corp.SVCC

$75K—

FAQ

What is Mineralys Therapeutics, Inc.'s public offering and shelf offering costs included in accounts payable and accrued liabilities?

Mineralys Therapeutics, Inc. (MLYS) reported public offering and shelf offering costs included in accounts payable and accrued liabilities of $7K in Q1 2026.

How has Mineralys Therapeutics, Inc.'s public offering and shelf offering costs included in accounts payable and accrued liabilities changed year-over-year?

Mineralys Therapeutics, Inc.'s public offering and shelf offering costs included in accounts payable and accrued liabilities decreased by 97.6% year-over-year, from $289K to $7K.

What does public offering and shelf offering costs included in accounts payable and accrued liabilities mean?

This represents costs associated with equity or debt offerings that have been accrued but not yet settled in cash, often recorded within accounts payable. It highlights liabilities related to capital raising activities that impact the balance sheet before the actual cash outflow occurs. Investors monitor this to assess the total cost burden of financing activities that may not be immediately visible in the cash flow statement.